bluebird bio (BLUE) to Present Interim bb2121 Phase 1 Data in Multiple Myeloma at Upcoming Conference

November 14, 2016 10:00 AM EST

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

bluebird bio, Inc. (Nasdaq: BLUE) announced that interim data from its study of bb2121, the company’s anti-BCMA CAR T cell therapy, currently in a Phase 1 trial of patients with relapsed/refractory multiple myeloma will be presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapies Symposium in Munich, Germany.

Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma

Date: Thursday, December 1, 2016, 17:40 CET (11:40 am ET)Session: Plenary Session 7



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News

Add Your Comment